ALKERMES | ALKS - Operating Expenses


ALKERMES reported $1.75B in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 538M Mar/2026
Acadia Pharmaceuticals USD 272.68M 6.08M Mar/2026
ALKERMES USD 1.75B 1.43B Mar/2026
Amgen USD 4.78B 1.12B Mar/2026
Biogen USD 1.96B 69.6M Mar/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Coherus Biosciences USD 51.83M 2.48M Dec/2025
Eli Lilly USD 10.02B 285M Mar/2026
Gilead Sciences USD 23.52B 18.55B Mar/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Ionis Pharmaceuticals USD 364M 54M Mar/2026
J&J USD 17.44B 1.53B Mar/2026
Malin Corporation EUR 1.1M 400K Dec/2024
Merck USD 18.17B 8.01B Mar/2026
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Neurocrine Biosciences USD 599.9M 22.3M Mar/2026
Otsuka Holdings JPY 512.13B 70.77B Mar/2026
Ovoca Bio EUR 1.16M 4.48M Jun/2025
Pfizer USD 90.1B 77.19B Mar/2026
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Vertex Pharmaceuticals USD 1.85B 78.6M Mar/2026